AffiliationMount Vernon Cancer Centre , Northwood , UK
MetadataShow full item record
AbstractThe concept of tumour hypoxia as a cause of radiation resistance has been prevalent for over 100 years. During this time, our understanding of tumour hypoxia has matured with the recognition that oxygen tension within a tumour is influenced by both diffusion and perfusion mechanisms. In parallel, clinical strategies to modify tumour hypoxia with the expectation that this will improve response to radiation have been developed and tested in clinical trials. Despite many disappointments, meta-analysis of the data on hypoxia modification confirms a significant impact on both tumour control and survival. Early trials evaluated hyperbaric oxygen followed by a generation of studies testing oxygen mimetics such as misonidazole, pimonidazole and etanidazole. One highly significant result stands out from the use of nimorazole in advanced laryngeal cancer with a significant advantage seen for locoregional control using this radiosensitiser. More recent studies have evaluated carbogen and nicotinamide targeting both diffusion related and perfusion related hypoxia. A significant survival advantage is seen in muscle invasive bladder cancer and also for locoregional control in hypopharygeal cancer associated with a low haemoglobin. New developments include the recognition that mitochondrial complex inhibitors reducing tumour oxygen consumption are potential radiosensitising agents and atovaquone is currently in clinical trials. One shortcoming of past hypoxia modifying trials is the failure to identify oxygenation status and select those patient with significant hypoxia. A range of biomarkers are now available including histological necrosis, immunohistochemical intrinsic markers such as CAIX and Glut 1 and hypoxia gene signatures which have been shown to predict outcome and will inform the next generation of hypoxia modifying clinical trials.
CitationClinical trials targeting hypoxia. 2018, Br J Radiol
JournalThe British Journal of Radiology
- Targeting tumour hypoxia: shifting focus from oxygen supply to demand.
- Authors: Coates JT, Skwarski M, Higgins GS
- Issue date: 2019 Jan
- Hypoxic sensitizer and cytotoxin for head and neck cancer.
- Authors: Lee DJ, Moini M, Giuliano J, Westra WH
- Issue date: 1996 May
- Nitroimidazoles as hypoxic cell radiosensitizers and hypoxia probes: misonidazole, myths and mistakes.
- Authors: Wardman P
- Issue date: 2019 Jan
- Enhancement of tumor perfusion and oxygenation by carbogen and nicotinamide during single- and multifraction irradiation.
- Authors: Fenton BM, Lord EM, Paoni SF
- Issue date: 2000 Jan
- Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma: hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen, and nicotinamide.
- Authors: Hoskin PJ, Saunders MI, Dische S
- Issue date: 1999 Oct 1